SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, [...] Read more »
Zoom to Release Financial Results for the Second Quarter of Fiscal Year 2026
SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, [...] Read more »
Namib Minerals Provides Corporate Update
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Namib Minerals (“Namib Minerals” or “the Company”), (Nasdaq: NAMM), an established African gold producer with a portfolio of mining and exploration [...] Read more »
Information on the total number of voting rights and shares
REGULATED INFORMATION
Information on the total number of voting rights and shares
Mont–Saint–Guibert [...] Read more »
Informations sur le nombre total de droits de vote et d'actions
INFORMATION RÉGLEMENTÉE
Informations sur le nombre total de droits de vote et d'actions
Mont–Saint–Guibert [...] Read more »
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
Mont–Saint–Guibert, Belgium – [...] Read more »
Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025
Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025
Mont–Saint–Guibert, Belgique – Mardi 29 [...] Read more »
Les Données de l'Étude Pivot DREAM de Nyxoah publiées dans le Journal of Clinical Sleep Medicine
Les Données de l'Étude Pivot DREAM de Nyxoah publiées dans le Journal of Clinical Sleep Medicine
Mont–Saint–Guibert, Belgique – 28 [...] Read more »
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine
Mont–Saint–Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm [...] Read more »
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A [...] Read more »